Factors that predict nursing dwell...

Factors that predict nursing dwelling placement in patients with Alzheimer's disease include worsening dementia, behavior disturbances, and caregiver lading However, most families prefer to retain patients with Alzheimer's disease at place of abode as long as possible. In addition, delaying nursing household placement may reduce overall health care splendors Geldmacher and colleagues studied the part of the cholinesterase inhibitor donepezil in delaying time to nursing hearthstone admission.

The investigation was an observational follow-up to several randomized, placebo-controlled trials investigating the therapeutic benefits of donepezil. At the completion of these trials, patients were invited to continue open-label treatment for up to 240 weeks. Data, including nursing hearth placement, were recorded, as were the date and reason for placement. Four arranges of patients were defined, depending upon duration of donepezil use and dosage. These clusters included the following: (1) minimal-use patients who received les than the minimum dosage, (2) early moderate-use patients who received adequate dosages however terminated early or did not participate in the open-label extension, (3) delayed-start patients who received adequate dosages no other than after entering the extension trial, and (4) maximal-use patients who received adequate dosages during the placebo-controlled phase and the extension. The principal result was time from entry in a placebo-controlled trial to nursing abiding-place placement. Different constructs were analyzed, depending forward the duration of successful participation in a clinical trial.

A total of 671 patients with mild to moderate dementia were included in the analyses. Estimated median times to first dementia-related nursing abode placement ranged from 44.7 month in the minimal-use cluster and 66.1 months in the maximal-use cluster A delay in first dementia-related nursing abiding-place placement of 21.4 months was associated with donepezil use of at least 5 mg daily for at least 36 to 48 weeks. A delay of 175 month to permanent nursing dwelling placement was associated with donepezil use of the same dosage and duration. Relative risk ratios (RRs) for nursing to one's home placement in the moderate-use clump were not significantly different from those in the minimal-use arrange but were significantly different from this form into groups in the delayed-start and maximal-use assemblages RRs for nursing home placement declined with longer donepezil use across all four assign places tos a trend that was consistent for the three cohort time fabricates analyzed.

According to the accrues of this study, cumulative sustained front to effective doses of donepezil delays time to nursing hearth placement when placement is for longer than brace weeks. Washout periods during the placebo-controlled trials attenuated donepezil's results suggesting that treatment of Alzheimer's disease with donepezil should be maintained before important benefits will come into view The authors doubt that selection bias influenced these be deriveds given the similarity of patient characteristics and a follow-up period of up to eight years. Donepezil appears to benefit one as well as the other cognitive function and behavioral symptoms.

Geldmacher D et al. Donepezil is associated with delayed nursing family placement in patients with Alzheimer's disease. J Am Geriatr Soc July 2003;51:937-44

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group